Shimohara K, Niida H, Okabe S
Department of Applied Pharmacology, Kyoto Pharmaceutical University, Japan.
Jpn J Pharmacol. 1990 Jun;53(2):275-9. doi: 10.1254/jjp.53.275.
Effects of a newly synthesized compound, KB-5492, on gastric lesions and gastric secretion were studied in rats. Oral KB-5492 inhibited the lesions induced by HCl.ethanol, HCl.aspirin, water-immersion stress, indomethacin, histamine and prednisolone at 30-300 mg/kg. The ED50 values varied from about 35 to 98 mg/kg. KB-5492 had no effect on gastric acid secretion even at 300 mg/kg. KB-5492 appeared to have a much more potent protective effect than a known anti-ulcer drug, sofalcone, against acute gastric lesions.
研究了一种新合成的化合物KB - 5492对大鼠胃损伤和胃分泌的影响。口服KB - 5492能抑制盐酸、乙醇、盐酸、阿司匹林、水浸应激、吲哚美辛、组胺和泼尼松龙诱导的损伤，剂量为30 - 300mg/kg。半数有效剂量（ED50）值约为35至98mg/kg。即使在300mg/kg的剂量下，KB - 5492对胃酸分泌也没有影响。与已知的抗溃疡药物索法酮相比，KB - 5492对急性胃损伤似乎具有更强的保护作用。
